| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues-Grant Revenues | 0 | - | - | - |
| Total revenues | 0 | 130 | - | 14 |
| Research and development | 3,651 | 3,152 | 2,951 | 2,415 |
| General and administrative | 2,741 | 2,543 | 2,907 | 2,911 |
| Total operating expenses | 6,392 | 5,695 | 5,858 | 5,326 |
| Loss from operations | -6,392 | -5,565 | -5,858 | -5,312 |
| Interest expense | 6 | 9 | - | 16 |
| Other income, net | - | - | 47 | - |
| Change in fair value of convertible promissory notes | 0 | 0 | - | - |
| Change in fair value of warrants | -1,044 | 956 | -989 | -6,669 |
| Gain on warrants expiration | 724 | - | - | - |
| Other income, net | 35 | 68 | - | 42 |
| Total other income, net | 1,797 | -897 | 1,036 | 6,695 |
| Net (loss) income | -4,595 | -6,462 | -4,822 | 1,383 |
| Net loss attributable to noncontrolling interest | -10 | -14 | -9 | -27 |
| Net (loss) income attributable to serina therapeutics, inc | -4,585 | -6,448 | -4,813 | 1,410 |
| Basic (in shares) | 10,339,000 | 10,004,000 | 9,756,000 | 8,851,000 |
| Basic (in usd per share) | -0.45 | -0.66 | -0.49 | 0.16 |
| Diluted ( in shares) | 10,339,000 | 10,004,000 | 9,756,000 | 10,751,000 |
| Diluted (in usd per share) | -0.45 | -0.66 | -0.49 | 0.13 |
Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc. (SER)